Allergan, Inc. and MAP Pharmaceuticals, Inc. Announce the Federal Trade Commission Has Granted Early Termination of Waiting

  Allergan, Inc. and MAP Pharmaceuticals, Inc. Announce the Federal Trade
  Commission Has Granted Early Termination of Waiting Period Under
  Hart-Scott-Rodino Act

Business Wire

IRVINE, Calif. & MOUNTAIN VIEW, Calif. -- February 7, 2013

Allergan, Inc. (NYSE: AGN) (“Allergan”) and MAP Pharmaceuticals, Inc. (NASDAQ:
MAPP) (“MAP”) today announced that the Federal Trade Commission has granted
early termination of the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended (the “HSR Act”), with respect to the
tender offer for all of the outstanding shares of common stock of MAP by
Groundhog Acquisition, Inc. (“Purchaser”), a wholly-owned subsidiary of

As previously announced, on January 31, 2013, Purchaser initiated a tender
offer to purchase all outstanding shares of common stock of MAP for $25.00 per
share, net to the seller in cash, without interest and less any applicable
withholding taxes. The tender offer is being made pursuant to an Agreement and
Plan of Merger, dated as of January 22, 2013, by and among Allergan, Purchaser
and MAP (the “Merger Agreement”).

The termination of the HSR Act waiting period satisfies one of the conditions
to the completion of the tender offer. Completion of the tender offer remains
subject to other customary conditions as set forth in the Offer to Purchase
filed by Purchaser and Allergan with the U.S. Securities and Exchange
Commission (the “SEC”) on January 31, 2013, including the tender of at least a
majority of the outstanding shares of common stock of MAP on a fully diluted
basis. The tender offer and withdrawal rights are scheduled to expire at 12:00
midnight, New York City time, on the night of February 28, 2013, unless
extended in accordance with the terms of the Merger Agreement and applicable
rules and regulations of the SEC.

About Allergan, Inc.

Allergan is a multi-specialty health care company established more than 60
years ago with a commitment to uncover the best of science and develop and
deliver innovative and meaningful treatments to help people reach their life’s
potential. Today, we have approximately 10,800 highly dedicated and talented
employees, global marketing and sales capabilities with a presence in more
than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals,
biologics, medical devices and over-the-counter consumer products, and
state-of-the-art resources in R&D, manufacturing and safety surveillance that
help millions of patients see more clearly, move more freely and express
themselves more fully. From our beginnings as an eye care company to our focus
today on several medical specialties, including eye care, neurosciences,
medical aesthetics, medical dermatology, breast aesthetics, obesity
intervention and urologics, Allergan is proud to celebrate more than 60 years
of medical advances and proud to support the patients and physicians who rely
on our products and the employees and communities in which we live and work.
For more information regarding Allergan, go to:

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and
commercializing new therapies to address undermet patient needs in neurology.
MAP is developing LEVADEX®, an orally inhaled investigational drug for the
acute treatment of migraine. The New Drug Application for LEVADEX® is
currently under review by the U.S. Food and Drug Administration. MAP has
entered into a collaboration agreement with Allergan to co-promote LEVADEX® to
neurologists and pain specialists in the U.S. and Canada. MAP also applies its
proprietary drug particle and inhalation technologies to generate new pipeline
opportunities by enhancing the therapeutic benefits of proven drugs, while
minimizing risk by capitalizing on their known safety, efficacy and
commercialization history. Additional information about MAP can be found at

Notice to Investors

This press release is neither an offer to purchase nor a solicitation of an
offer to sell securities. The solicitation and the offer to buy the
outstanding shares of common stock of MAP is being made pursuant to the Tender
Offer Statement on Schedule TO filed by Purchaser and Allergan with the SEC on
January 31, 2013. MAP has also filed a Solicitation/Recommendation Statement
on Schedule 14D-9 with respect to the tender offer on January 31, 2013. MAP
stockholders and other investors are strongly advised to read the tender offer
materials (including the Offer to Purchase, the related Letter of Transmittal
and certain other tender offer documents) and the Solicitation/Recommendation
Statement because they contain important information which should be read
carefully before any decision is made with respect to the tender offer. These
materials have been sent free of charge to all stockholders of MAP. The Tender
Offer Statement and the Solicitation/Recommendation Statement (and all other
tender offer documents filed with the SEC) are also available for free on the
SEC’s website: The Schedule TO (including the Offer to Purchase
and related materials) and the Schedule 14D-9 (including the
Solicitation/Recommendation Statement) may also be obtained for free by
contacting the Information Agent at (800) 347-4750.

In addition to the Offer to Purchase, the related Letter of Transmittal and
certain other tender offer documents, Allergan and MAP file annual, quarterly
and special reports, proxy statements and other information with the SEC. You
may read and copy any reports, statements or other information filed by
Allergan and MAP at the SEC public reference room at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further
information on the public reference room. Allergan’s and MAP’s filings with
the SEC are also available to the public from commercial document-retrieval
services and at the website maintained by the SEC at

Forward-Looking Statements

This press release contains “forward-looking statements,” relating to the
acquisition of MAP by Allergan. All statements other than historical facts
included in this press release, including, but not limited to, statements
regarding the timing, and the closing of the tender offer transaction and any
assumptions underlying the foregoing, are forward-looking statements. These
statements are based on current expectations of future events. If underlying
assumptions prove inaccurate or unknown, or unknown risks or uncertainties
materialize, actual results could vary materially from Allergan’s expectations
and projections. Risks and uncertainties include, among other things,
uncertainties as to how many of MAP’s stockholders will tender their stock in
the tender offer; the possibility that various closing conditions to the
tender offer and merger transactions may not be satisfied or waived, including
that a governmental entity may prohibit, delay, or refuse to grant approval
for the consummation of the transaction; that the U.S. Food and Drug
Administration or other regulatory authorities do not approve LEVADEX® in the
manner desired by MAP and Allergan, on a timely basis, or at all; that there
is a material adverse change to MAP; that the integration of MAP’s business
into Allergan is not as successful as expected; the failure of Allergan to
achieve the expected financial and commercial results from the transaction;
other business effects, including effects of industry, economic or political
conditions outside the company’s control; transaction costs; actual or
contingent liabilities; as well as other cautionary statements contained
elsewhere herein and in the companies’ periodic reports filed with the SEC
including current reports on Form 8-K, quarterly reports on Form 10-Q and
annual reports on Form 10-K. Given these uncertainties, you should not place
undue reliance on these forward-looking statements, which apply only as of the
date of this press release. Allergan and MAP expressly disclaim any intent or
obligation to update these forward-looking statements except as required by
law. Additional information about Allergan is available at or
you can contact the Allergan Investor Relations Department by calling
714-246-4636. Additional information about MAP is available at


D.F. King & Co., Inc. (212) 269-5550 or (800) 347-4750
Allergan Investor Relations (714) 246-4636
Media Inquiries (Bonnie Jacobs) (714) 246-5134
Press spacebar to pause and continue. Press esc to stop.